HAVCR2 and neoplasm: In the field of tumor immunotherapy research, the six immune checkpoints PDCD1, CD274, CTLA-4, LAG-3, TIGIT, and HAVCR2 can inhibit the proliferation, activation and effector functions of T cells, and maintain the immune homeostasis in the body.